Abstract | Cancer therapy makes patients sick. The therapies that are available to clinicians allow them to successfully control nausea, emesis and pain. However, this is not the case for a number of other symptoms that include fatigue, distractibility, poor memory, and diminished interest in previously pleasurable activities. These symptoms cluster during the course of cancer therapy and impair patient quality of life, limit therapy options and do not always resolve at the cessation of treatment. It is possible to describe the intensity and temporal features of symptoms and assess their relationship with the inflammatory response that is associated with cancer and cancer therapy. At the preclinical level, sophisticated animal models still need to be deployed to study the causal role of inflammation in specific components of cancer-related symptoms. Various approaches can be optimally combined in a translational symptom research pathway to provide a framework for assessing in a systematic manner the neurobehavioral toxicity of existing and newly developed cancer therapies. Ultimately, this knowledge will allow derivation of mechanism-based interventions to prevent or alleviate cancer-related symptoms.
Introduction
Advances in cancer detection have allowed many people to be diagnosed relatively early in the disease process. After excision of even relatively small tumours, most patients will receive additional adjunctive therapy, which typically includes chemotherapy and/or radiotherapy to limit proliferation of residual cancer cells and prevent recurrence of the cancer. These therapies that aim to prevent cancer cell proliferation also damage normal tissues and impair homeostasis. As a result, many patients who felt reasonably healthy before diagnosis feel profoundly sick because of the treatments that are intended to cure them.
When patients learn that they have cancer they are concerned about the symptoms that they will experience. These concerns are well-founded: approximately 70% of outpatients will experience pain or will take analgesics to manage pain. The prevalence of pain has remained the same in studies conducted in patients almost two decades apart. 1, 2 Pain, however, is not an isolated symptom. Patients undergoing active therapy are more likely to report other symptoms as more severe than pain, including fatigue, inability to get things done, distress, worrying, and disturbed sleep. 3 A recent study of cancer survivors found one in four patients reported high levels of symptoms 1 year after diagnosis, with pain, fatigue, inability to concentrate and sleep disturbances being prominent symptoms. There was no difference in symptom burden between those who had recently completed treatment and those who remained on therapy. 4 Some cancer-related symptoms are the direct result of disease and may improve with effective cancer treatment. For example, reduction in pain may be an important outcome for curative therapies. 5 However, other symptoms, especially neuropathy, fatigue, sleep disturbance, cognitive dysfunction, and alterations in mood, dramatically increase during and immediately after cancer therapy. 3 As patients survive cancer for increasingly longer periods of time, persistent residual treatmentrelated symptoms are becoming more prevalent and pose an increasing barrier to the resumption of pre-disease functioning. Treatment-related symptoms can directly affect survival if they become so severe that patients abandon potentially curative therapies or if symptoms cause treatment delays. Post-treatment symptoms can also limit vocational activity and inhibit social recovery. 6 Conversely, effective control of treatment-related symptoms could enhance therapeutic outcomes by improving patient health status, minimizing toxicities that impair function, and increasing adherence to curative treatments. Such symptom control not only enhances or maintains health-related quality of life, but also potentially increases survival.
Cytotoxic therapies are expected to produce symptoms because normal tissue function is disrupted as cancer cells are killed. It was hoped that targeted anticancer therapies would destroy cancer cells specifically and, therefore, cause less general toxicity; 7 however, a different profile of toxic effects has emerged with these agents, such as hypertension, cardiac toxicity, thyroid dysfunction, hand-foot syndrome, and skin reactions, in addition to the more-commonly observed adverse effects of nausea, diarrhoea and fatigue; 8 each novel agent has its own unique toxicity profile. However, fatigue is often a common treatment-related symptom experienced by patients treated with targeted therapies, and can prevent patients from adhering to chronic therapy, which is often essential to maintain molecular remission.
Patients undergoing treatment and experiencing symptoms are compelled to draw analogies with other conditions that present the same sort of deficits, including clinical depression and dementia. Patients may also attribute their symptoms to the stress of having a lifethreatening disease, the hectic schedule of treatment requirements, and changes in work and family life. There is increasing evidence that the symptoms cancer patients experience correspond to a collection of neurobehavioural symptoms or behavioural comorbidities, 9 which strongly suggests that treatment and/or cancer are perturbing central neuronal function.
In this Review article, we examine the nature and mecha nisms of the behavioural comorbidities that are experienced by patients with cancer. We discuss how cancerrelated symptoms develop and can remain after termination of curative treatment, and what can be done at the clinical and preclinical levels to better understand their mechanisms and identify appropriate treatments. We will draw from several disciplines including clinical psycho logy, behavioural neuro science, behavioural pharmaco logy, immunology and psychoneuroimmunology.
Symptom measures and trajectories
Symptoms are defined as sensations or perceptions of changes related to health function that an individual experiences. 10 Symptoms do not remain at the perceptual level. They give rise to feelings of distress that can culminate in profoundly disturbing negative emotions in response to aggravating conditions. In clinical oncology, symptoms are usually not assessed by external observation. They are reported by patients in the form of health complaints. These complaints can be made more specific by asking patients to fill out standardized questionnaires on a given symptom or a set of symptoms. For instance, patients can rate the severity of a symptom such as fatigue or pain on a numeric rating scale from 0 (symptom not present) to 10 (the highest intensity of the symptom they can think of). Supplementary questionnaires can be used to assess the quality of the symptom, its temporal pattern and duration, and its interference with the patient's functioning. 11 Although most clinicians agree that self-report is our best source of information about symptoms, other measures of performance (such as, cognitive assessment and activity measures) can greatly supplement our understanding of symptoms. It is relatively standard in both clinical practice and clinical research for patients to rate a set of prevalent symptoms together on a single multisymptom assessment measure, such as the MD Anderson Symptom Inventory (MDASI). 12 Several common observations emerge from studies of symptoms in cancer patients (Box 1 and Figure 1) . What is immediately apparent in patients with cancer is that they report several symptoms instead of only one symptom at any given time during cancer therapy. The intensity of these symptoms varies with length of time from the start of treatment, with the peak of treatmentrelated symptoms generally occurring a few weeks after the initiation of therapy. 13 Variation of symptom type and severity over time corresponds with what is called the symptom trajectory. In addition, subsets of symptoms have a higher probability of co-occurring. Multiple symptoms that follow the same time course in response to disease or treatment have been termed symptom clusters. 14, 15 Symptom clusters vary according to the type of cancer and cancer therapy, and the time at which symptoms are assessed (Box 1). Symptom clustering Key points ■ Overwhelming fatigue, distractibility, poor memory, and lack of interest in activities that used to be pleasurable are among the most distressing symptoms patients experience in response to cancer therapy ■ The trajectory of these symptoms can be studied over time together with their co-occurrence in the form of clusters and their impact on patients' daily functioning ■ There is already evidence that the development of cancer-related symptoms is associated with an increased expression of inflammatory mediators ■ Animal studies have confirmed that cancer therapy induces profound neurobehavioural changes that are associated with inflammation; attempts to model key symptoms in cancer patients are still scarce ■ Individual differences in symptom severity in response to cancer therapy provide a unique perspective on the genomics of symptoms that should be incorporated in animal models of cancer-related symptoms ■ Preclinical and clinical approaches can be combined in a translational research pathway that provides a framework for addressing the neurobehavioural toxicities of cancer therapies
Box 1 | Prevalence and clustering of symptoms in patients with cancer
The prevalence and severity of symptoms produced by cancer and its therapy vary. Pain, fatigue, sleep disturbances, emotional distress, and difficulties with concentration commonly co-occur or 'cluster' across various diseases and treatments. 9, 98 It has been postulated that this cluster represents symptoms that have common underlying mechanisms. An example of clustering of cancerrelated symptoms is presented in Figure 1b , based on the data collected in one large study of patients undergoing treatment at a tertiary cancer centre. The 527 patients enrolled in this study had heterogeneous cancers and cancer treatment, and completed the MD Anderson Symptom Inventory (MDASI). 12 The following symptoms were rated as being at least moderately severe (that is, 5 or greater on the MDASI 0 to 10 scale): fatigue (59%), inability to get things done (51%), weakness (50%), worry (42%), distress (38%), disturbed sleep (41%), drowsiness (41%), lack of appetite (39%), sadness (32%), pain (34%), and difficulty remembering (30%). 12 Another study analyzed the MDASI symptom ratings of 1,433 patients with cancer from five different countries. 99 In each sample, fatigue was the most severe symptom. For the combined sample, highly rated symptoms included disturbed sleep, distress, lack of appetite, drowsiness, pain, and sadness. Symptom clustering is not always stable and depends on many factors including occurrence versus severity of symptom, the instrument used, the type of cancer, the modalities of treatment, and the time points at which symptoms are evaluated. The general consensus in the field is that even if there is sufficient evidence for recognizing the co-occurrence of symptoms of fatigue, insomnia, pain, depression, and cognitive dysfunction, the way these symptoms cluster and the underlying mechanisms of clustering require further research. 19, [100] [101] [102] [103] REVIEWS also depends on the method of scoring and the mode of analysis of the data. In general, considering occurrence of symptoms gives less-sensitive clustering information than including severity rating mainly because of the dichotomous nature of occurrence. 16 As illustrated by the cluster analysis (Figure 1b) , symptoms that represent negative effects (such as, sadness and distress) are most often related to items that portray fatigue and lack of motivation. These subsets are also related to reports of cognitive slowing with difficulties in paying attention and remembering. 17 We are far from understanding the mechanisms underlying the development of treatment-related symptom clusters. However, there is a growing awareness that common biological mechanisms, such as an inflammatory response produced by disease or treatment, endocrine impairment, and haematopoietic dysfunction, may cause or contribute to some of these symptoms at the same time. 9, 18, 19 Figure 1a presents an example of symptom trajectories in patients with colorectal cancer, oesophageal cancer, and non-small-cell lung cancer. 20 Fatigue emerges as the predominant symptom followed by disturbed sleep, difficulty swallowing, lack of appetite, pain, and distress. An important aspect of symptom trajectories is their interindividual variability. Despite the standardized cancer therapy that is now administered in most cancer wards, some patients develop high levels of symptoms whereas others report very little variation in their symptom trajectory. This is illustrated in Figure 2 by an example taken 
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REVIEWS from patients with head and neck cancer over the course of approximately 7 weeks of chemotherapy, radiotherapy or a combination of these treatments. 21 The reasons for these individual differences are not yet known, despite their importance for personalized care. We discuss this important issue later.
Pain has been the most intensively studied symptom in clinical oncology, in part because of its prevalence but also because it is such a well recognized symptom in medical care, in terms of functional impact and medical insurance coverage. Several excellent reviews on pain in cancer patients and animal models of cancer pain are already available, 22-24 and we will not add to this abundant literature. Instead, we will focus on the symptom cluster that includes fatigue, insomnia, depressed mood and cognitive impairment. The mechanisms and treatment of this symptom cluster remain elusive despite their very high prevalence both during and after cancer therapy.
Inflammation-induced symptoms
Cleeland and his colleagues were among the first researchers to propose an analogy between behavioural comorbidities occurring in response to cancer treatment and the clinical signs of sickness caused by inflammation. 18 Sickness behaviour refers to the coordinated set of originally adaptive behavioural changes that develop in ill individuals during the course of an infection to promote survival. 25 These behavioural changes include lethargy, sleepiness, social withdrawal, loss of appetite, reduced body care, and decreased ability to concentrate. These changes are orchestrated in the brain and represent the expression of a motivational state that reorganizes the priorities of the organism to cope with infection or other insults targeting the immune system. The analogy made by Cleeland and his colleagues was not only in terms of clinical manifestations but also in terms of mechanisms. It was proposed that cancer and cancer therapy trigger the release of inflammatory mediators that ultimately impact on the brain to induce signs and feelings of sickness. The mechanisms of inflammation-induced sickness are summarized in Box 2.
The possibility that inflammation is the mediating process in the relationship between cancer therapy and symptoms is very much in line with the long history of the relationship between cancer and inflammation. 26 Inflammation is present at every stage of tumour progression. Chronic inflammation contributes to cancer initi ation, promotion, and progression. 27 In addition to the reciprocal inflammatory relationships between neoplastic cells and other cell types in the microenvironment of the tumour, the trauma associated with the surgical pro cedure causes the release of inflammatory mediators. This is especially the case during visceral surgery, 28 but enhanced production of proinflammatory cytokines is also noted in patients submitted to various forms of breast reconstruction after mastectomy. 29 In recognizing the functional relationship between surgical trauma and inflammation, the inflammatory response to surgical trauma is currently examined as a possible cause for the postoperative delirium and cognitive dysfunction that commonly occurs during the post-operative period, especi ally in older patients. 30, 31 Chemotherapy and radio therapy are known to induce a 'cytokine storm' that involves many immune and non-immune cell types and various cytokines (for example, chemokines to proinflammatory cytokines and growth factors). [32] [33] [34] Because this cytokine storm can lead to various forms of multi-organ failure, the administration of potent antiinflammatory drugs, usually steroids, is required to limit its adverse consequences. The mechanisms that occur at the origin of the cytokine storm induced by cancer therapy are not fully elucidated. They probably involve damage-associated molecules that are released into the extracellular space by necrotic and apoptotic cells (Box 2 and Figure 3) .
Cancer, cancer therapy, and inflammation can collectively result in profound alterations in physical and mental functioning. The proposed analogy between inflammation-induced sickness and cancer-related symptoms provided the necessary impetus for the clinical exploration of associations between biomarkers of inflammation and behavioural comorbidities in cancer patients. It was predicted that symptomatic patients with cancer should present with higher levels of proinflammatory cytokines or other inflammatory mediators than individuals with no cancer. In addition, the association between symptoms and biomarkers of inflammation could last longer than the period of cancer therapy and be present in cancer survivors afflicted with behavioural comorbidities. Both predictions were tested in patients with breast cancer by assessing the relationship between inflammation and symptoms in patients who underwent chemotherapy and/or radiotherapy. 9 The predictions were shown to be valid despite the difficulties owing to the lack of standardization in the measurement of biomarkers of inflammation, and despite the fact that circulating cytokines do not reflect what is happening in the organ(s) in which tumour cells are present or in the brain where symptoms ultimately originate.
In one study of women who had gone through primary and adjunctive treatment for early stage breast cancer, 60% complained about fatigue and sleep disorders and 25% had elevated depressive symptoms. 35 Those women who had just finished chemotherapy had higher levels of all symptoms that were associated with increased levels of the soluble tumour necrosis factor (TNF) receptor II, a marker of TNF-α signalling. 35 Fatigue measured by the Fatigue Symptom Inventory, a 14-item valid and reliable scale developed for measuring symptoms of fatigue in cancer patients, 36 was positively associated with this marker. In a study of patients treated with radiotherapy for breast or prostate cancer, changes in serum levels of C-reactive protein and interleukin (IL)-1 receptor antagonist were positively associated with increases in fatigue symptoms. 37 Inflammatory cytokines act as intercellular autocrine, juxtacrine and paracrine communication signals in the microenvironment in which they are produced. It is not clear whether circulating cytokines reflect 'spill over' of molecules released locally from the site of inflam mation or if they are part of an inflammatory milieu that influences tissue-specific activity. Most of the evidence is in favour of the 'spill over' interpretation. Induction of bacterial peritonitis in mice, for instance, is associated with systemic inflammation as measured by circulating cytokines, but the subsequent development of inflammation in the lungs requires the local recruitment of polymorphonuclear leucocytes or the sequestration of neutrophils into the pulmonary vasculature. 38 In the same manner, the sustained release of proinflammatory cytokines into the systemic circulation that accompanies acute pancreatitis is associated with signs of inflammation only in the peritoneal compartment, whereas anti-inflammatory activity is present in the circulating compartment. 39 Induction of sickness behaviour in response to lipopolysaccharide is associated with a generalized inflammatory response but the propagation of peripheral inflammation to the brain does not occur via this general response pathway (Box 2 and Figure 3) . Thus, circulating levels of cytokines can be used as biomarkers of inflammation but do not necessarily inform their functional role.
From a methodological viewpoint, the best approach to gain an insight into the relationship between inflammation and symptoms would be to measure cytokines in the tumour microenvironment. This is possible in some clinical situations, such as ovarian cancer in which cytokines can be assayed in the ascites fluid surrounding the tumour. In patients awaiting surgery for a pelvic mass suspected for ovarian cancer, the most discriminative measure between patients with tumours of low Box 2 | Inflammation-induced sickness Inflammation-induced sickness has been studied mainly in the context of peripheral activation of the innate immune system by pathogen-associated molecules such as lipopolysaccharide (LPS) that target toll-like receptors (TLRs) at the membrane of innate immune cells. 104 Activation of TLRs induces production of inflammatory cytokines via activation of NF-κB and MAPK. In the context of chemotherapy and radiotherapy, the inflammatory response is triggered by molecules released by necrotic and apoptotic cells. These molecules include high mobility group box protein 1, heat shock proteins and S100 proteins. These proteins engage TLRs and the receptor for advanced glycation end products that signal through NF-κB pathways. 105 The resulting inflammation propagates to the brain via several parallel immune-to-brain communication pathways (Figure 3) . The relative importance of each of these pathways depends on the response to inflammation. Behavioural responses are mediated by afferent neural pathways, whereas neuroendocrine and fever responses are mediated by humoural pathways involving circulating pathogen-associated molecular patterns. Cytokines are ultimately responsible for the changes in behaviour, endocrine functions and metabolism that characterize the host response to inflammation. 106 The neurocircuitry of inflammation-induced sickness has been studied in animals injected with LPS and in humans given low doses of endotoxin or typhoid vaccine. Intraperitoneal administration of LPS to rats signals the brain via the vagus nerves and activates viscerosensory nuclei that are located in the caudal brainstem. 107, 108 The activation of stress-related brain areas contrasts with the deactivation of brain areas that are involved in positively-mediated behaviour, which include the motor cortex, piriform and cingulate cortex, together with the nucleus accumbens and locus coeruleus. 109 Fatigue and/or lethargy seem to be associated with reduced activation of dopaminergic neurons in the ventral tegmental area, histaminergic neurons in the ventral tuberomamillary nucleus, and orexin neurons in the lateral hypothalamus. malignant potential and patients with advanced-stage ovarian cancer was the vegetative dimension of depression assessed by the Center of Epidemiologic Studies Depression Scale. 40 Patients with early stage ovarian cancer had an intermediate score on this scale. The dimension of vegetative depression includes an assessment of motivational components very similar to the psychological dimension of fatigue (for example, keeping your mind on what you are doing), in addition to reduced appetite and sleep loss. 41 In both the plasma and ascites of patients with invasive ovarian cancer, IL-6 levels were high, and patients with advanced-stage ovarian cancer had the highest levels of IL-6. In addition, there was a positive correlation between IL-6 levels and vegetative depression. 40 When the tumour micro environment is not easily accessible, an alternative is to measure activation of intracellular cytokine signalling pathways in circulating immune cells or to assess the ability of these cells to produce cytokines in response to a standardized stimulation, such as lipopolysac charide. This assessment can be done on whole blood cell cultures or on isolated populations of peripheral blood mono nuclear cells. 42, 43 Despite its relatively common use in other medical disciplines such as biolo gical psychiatry, this approach is rarely favoured in clinical oncology probably because of the ease of measuring cytokines in serum or plasma of cancer patients.
The correlative nature of studies on inflammation and symptoms in patients with cancer does not allow any causal inference. What is striking, however, is that very similar symptoms to those reported in response to cancer therapy have been observed in patients with kidney cancer or metastatic melanoma treated with interferon (IFN)-α and/or IL-2. In these patients, cytokine administration invariably induces the neurovegetative symptoms of depression, with a predominance of fatigue, decreased appetite and sleep disorders. In about one third to one half of the patients, affective symptoms (decreased sensi tivity to reward, feelings of guilt and worthlessness, suicidal thoughts) developed but only after several days or weeks of treatment. 44 It is important to note that the occurrence of symptoms of depression and fatigue is associated with inflammation-induced activation of enzymatic pathways involved in the biosynthesis of neurotransmitters (Box 3 and Figure 4 ).
Animal models of cancer symptoms
There is evidence that tumours and cancer therapy lead to profound behavioural alterations in laboratory animals and that these behavioural alterations are associated with biomarkers of inflammation. 45 For instance, mammary tumours induced in rats by exposure to the carcinogen N-nitroso-N-methylurea were found to be associated with cognitive impairments in a radial-arm maze and an object-recognition memory test. 46 In the first test, rats must use environmental cues to orient themselves in a maze and find the arm of the maze in which a food reward is presented. In the second test, rats are presented with a novel object that they spontaneously explore in contrast to an already familiar object.
Box 3 | The biochemistry of inflammation-induced depression and fatigue
Inflammation induces depression and fatigue. Different mechanisms downstream of inflammation probably mediate depression and fatigue. There is evidence that inflammation-associated depression is mediated by activation of the tryptophan-degradation pathway, which affects glutamatergic neurotransmission. By contrast, inflammation-associated fatigue is mediated by a relative deficit in tetrahydrobiopterin that ultimately affects dopaminergic neurotransmission. 95 Proinflammatory cytokines activate genes controlling cellular proliferation, differentiation of cells, and genes that regulate metabolism. Low-grade inflammation activates both indoleamine 2,3 dioxygenase (IDO; targets tryptophan metabolism) and guanosine triphosphate cyclohydrolase-1 (GTP-CH1; indirectly targets tryptophan and phenylalanine metabolism). Both enzymes are expressed in a variety of immune and non-immune cells. IDO degrades the essential amino acid tryptophan along the kynurenine pathway. The degradation of tryptophan also generates neurotoxic metabolites such as 3-hydroxykynurenine and quinolinic acid. Activation of IDO, as measured by decreased circulating levels of tryptophan and increased levels of kynurenine, is associated with lower quality of life in patients with colorectal cancer. 111 The same enzyme is activated in cancer patients treated with interferon (IFN)-α and the lower the concentrations of circulating tryptophan the higher the symptoms of depression. 112 In mice, inflammationinduced depressive-behaviour is abrogated by antagonism of IDO. 68, 113 These findings are strongly suggestive of a causal role of IDO in inflammation-associated depression. 83 Deficit in the biosynthesis of dopamine, evidenced indirectly by an increase in the ratio of phenylalanine to tyrosine, has been documented in patients with cancer treated with IFN-α and could be responsible for psychomotor retardation. 84 It is also found in older patients with low-grade inflammation and it has been correlated with neurovegetative symptoms including sleep disturbances, digestive symptoms, fatigue, sickness, and motor symptoms. In the same population, increased tryptophan degradation was associated with the depressive symptoms of lassitude, reduced motivation, anorexia, and pessimism. Recognition is inferred from the difference in the time spent assessing the two objects. Depressive-like behaviour can be measured by increased immobility in the forced-swim test. In this test, animals are put in a small bucket filled with water. Normal animals swim vigorously to try to find an escape while 'depressed' animals quickly stop swimming and just float with a minimum of movements to maintain their head out of the water. The anhedonic component of depressive-like behaviour can be assessed by reduced sucrose preference. 47 Both measures of depressive-like behaviour were also enhanced in rats with mammary tumours. 48 Female mice injected with syngeneic ovarian carcinoma cells displayed evidence of depressive-like behaviour as assessed by decreased sucrose preference. 49 In both cases, altered behaviour was associated with increased expression of proinflammatory cytokines at the periphery and in the brain, although the causality was not tested.
Administration of chemotherapeutic agents such as cisplatin, 5-fluorouracil, paclitaxel, methotrexate, or doxorubicin alone or in combination with cyclophosphamide to healthy animals reduced spontaneous motor activity, decreased food intake, disturbed sleep patterns and nycthemeral rhythms, and induced cognitive dysfunction. [50] [51] [52] [53] [54] [55] [56] [57] Various pharmacotherapies and supplements targeting oxidative stress and inflammation have been tested for their ability to alleviate the behavioural effects of chemotherapy. 52, 57, 58 The possibility of using stem-cell transplantation to alleviate cognitive dysfunction induced by cranial radiotherapy has even been examined in a recent study carried out in irradiated athymic nude rats. 59 However, since most intervention studies have been carried out in healthy animals there is still the caveat of a potential reduction in chemotherapeutic efficacy that needs to be considered before these results can be applied to the clinical condition.
Another important limitation of behavioural studies in laboratory animals is the difficulty of equating changes in behaviour observed in animals with symptoms reported by patients. In many cases, reasoning is by analogy or by successive elimination. In an attempt to model chemo therapy-related fatigue, mice were treated daily for 5 consecutive days with a subtoxic dose of paclitaxel. Not surprisingly, paclitaxel-treated mice moved around less and did not use the running wheel during the first 2 or 3 weeks after treatment. 50 To support their claim that these behavioural alterations are equivalent to fatigue, the authors of this study took great care to show that the behavioural alterations observed in the third week post-treatment were not associated with differences in sleep patterns and in motor coordination, in contrast to the behavioural alterations that were observed on the first week post-treatment. However, they did not consider another possible confounding factor represented by the development of neuropathy in the paws of paclitaxel-treated mice. 60 A similar approach based on pharmacological tools was used to dissociate malaise from fatigue in cisplatin-treated rats. 51, 58 Rats lack an emetic response but do engage in the consumption of kaolin clay when made sick by toxins, and this behaviour is antagonized by anti-emetic drugs. Cisplatin reduced food intake, stimulated kaolin consumption, decreased gastric emptying and reduced locomotor activity. Administration of the serotonin 5-HT3 receptor antagonist ondansetron, which is used to prevent nausea and emesis during cancer therapy, attenuated the effects of cisplatin on food intake and kaolin consumption but had no effect on gastric emptying and locomotor acti vity. Dexamethasone blocked all the behavioural effects of cisplatin and restored gastric emptying. 58 These results indicate that reduced food intake and kaolin consumption are good indicators of cisplatin-induced malaise.
Measures of changes in spontaneous activities need to be complemented by assessment of sensory, motor, cognitive, and affective behaviours. Very sophisticated behavioural techniques have been developed by behaviourists, mainly in the context of behavioural phenotyping of transgenic mice, behavioural neuroscience, and behavioural pharmacology and toxicology. [61] [62] [63] These techniques can be easily applied to the study of symptoms induced by cancer and cancer therapy in laboratory rodents. For example, in the field of depression, researchers have developed animal models of depression that meet scientific criteria of validity including construct validity (same causal factors as those for the human condition), face validity (similar clinical signs, such as anhedonia, in the animal model and the human condition), and predictive validity (treatments active in the animal model are able to reduce the symptoms in clinics). 64 The sensitivity of behavioural assays of depressive-like behaviour to the development of tumours induced by a carcino gen has already been noted. 48 In the field of fatigue, most of the studies in exercise physiology have focused on the ability to withstand treadmill exercise
Box 4 | Parsing components of cancer-related symptoms
To study the mechanisms of cancer-related symptoms, it is necessary to translate them into objective behavioural and physiological measures ( Figure 5 ). 114 Animal models are useful because they can be designed to measure the various dimensions of symptoms. This approach is illustrated by two behavioural tests used to study motivation: a concurrent choice task ( Figure 6 ) and a progressive ratio test (Figure 7) . 96, 97 Both tests evaluate the cost an animal is ready to pay to get access to a given commodity (here, a food reward). Although impaired performance in these tasks would suggest a motivational deficit, additional behavioural tests would be needed to evaluate alternative explanations. Chemotherapy could induce a motor impairment that makes the animal unable to respond quickly or to sustain effort. This can be examined using tests of motor function. Chemotherapy could also alter the affective or hedonic response to the preferred food, resulting in a less-valued outcome and, consequently, decreased effort. To evaluate the latter hypothesis, additional tests that assess emotional 'liking/disliking' (Figure 5 ), such as response vigour, facial affect, and drug discrimination, would be needed. [4] [5] [6] [115] [116] [117] The inflammatory changes induced by cancer and its treatment can affect any or all of the psychobiological processes depicted in Figure 5 , and an alteration in just one component is sufficient to modify behaviour in several tasks. Therefore, it can be predicted that various cancer therapies sharing the same neuroimmune mechanisms will induce a similar pattern or spectrum of behavioural changes and, a contrario, that cancer therapies with different mechanisms of action will induce distinct patterns of behavioural change. These patterns can be further used to study the mechanisms of action of cancer therapy on symptoms and to test the efficacy of preventive and curative treatments.
with the implicit assumption that fatigue signals originate from peripheral sources. Run time to fatigue in mice is increased after muscle-damaging downhill exercise and this symptom is associated with increased muscle inflammatory cytokines. However, the same cytokine response also occurs in the brain. 65 Furthermore, depletion of brain macrophages by intracerebroventricular injections of clodronate-filled liposomes that specifically kill brain macrophages was found to enhance treadmill performance after downhill runs. 66 These results demonstrate that there is an important central component in fatigue. This central component of fatigue has dimensions of affect and motivation that probably predate task failure and can be studied objectively in mice using appropriate behavioural techniques (Box 4 and Figures 5-7) .
Future perspectives
Given our discussion of the relationship between inflammation and cancer-related symptoms, it should be sufficient to give an anti-inflammatory treatment that targets proinflammatory cytokines to alleviate symptoms in cancer patients. However, this is not as easy as it seems. As of April 13, 2012, the ClinicalTrials.gov website lists five trials of minocycline for reducing symptom burden or neuropathy in cancer patients. Minocyline is a second-generation tetraycline that has interesting anti-inflammatory properties both at the periphery and in the central nervous system because of its ability to cross the blood-brain barrier. The ability of minocycline to downregulate microglia activation confers some neuroprotective activity. 67 There is already evidence that the attenuation of microglial activation by minocycline prevents the development of neuropathic pain and inflammation-induced depressive-like behaviour in animal models. 60, [68] [69] [70] However, there is no evidence yet that minocycline can act in a curative manner. In the case of HIV infection, for instance, minocycline gave very encouraging results in the prevention of encephalitis and neurodegeneration in macaques infected with the simian equivalent of HIV. 71 However, minocycline treatment did not alleviate HIV-associated cognitive impairment 72 and had no effect on biomarkers of immune activation and inflammation in viremic individuals. 73 On the basis of these findings, minocycline is probably a treatment of choice only when it can be initiated before the development of inflammation.
Another possibility is the use of anti-cytokine strategies. For instance, in the case of TNF-α, several antagonists (such as etanercept, infliximab, and adalimumab) have been developed for the treatment of rheumatoid arthritis and psoriasis. Their efficacy is supported by several randomized controlled studies and meta-analyses despite their relatively moderate safety profile. 74, 75 These drugs have been tested for alleviation of symptom burden in patients with cancer with very contrasting results. [76] [77] [78] An improvement in tolerability of dose-intensive chemotherapy with docetaxel in patients with advanced-stage malignancies was reported with etanercept, particularly in terms of fatigue. 76 However, the combination of infliximab and docetaxel worsened fatigue and global quality of life scores in another trial carried out in patients with non-small-cell lung cancer. 78 This trial had to be stopped because of lack of effect of infliximab on anorexia/cachexia, which was the primary outcome, and the possibility of severe side effects. The reasons for the discrepancies between these two trials are not immediately apparent.
Many pharmacological and non-pharmacologicalbased forms of intervention have been proposed for management of symptoms in patients with cancer. In the case of fatigue, it is clear that none of the modalities that have been examined, from anti-inflammatory drugs to physical exercise via psychostimulants, dietary supplements, and psychosocial interventions, is fully effective. 79, 80 This situation calls for a profound re-examination of the way symptoms are approached in clinical oncology. The current therapeutic landscape in cancer drug development is dominated by the search for drugs that suppress malignant and premalignant cells and prevent their dissemination. Much less importance is attached to treatment-related symptoms and toxicities despite their prevalence and their impact on adherence to anti cancer treatment. There are still many barriers to research in symptom-management drug development including the very limited knowledge on the biological processes that mediate symptom development and maintenance, the co-occurrence of multiple symptoms, and the difficulty of enrolling patients with high symptom burden in clinical trials. A new translational pathway to develop symptomfocused therapies is clearly needed. Its components have already been listed and include: focusing on treatment-related symptoms; making use of individual differences in symptom expression to identify genetic and epigenetic risk factors for developing severe symptom trajectories; increasing efforts to produce animal models of cancer-related symptoms to test causality; and investigating symptom interventions through controlled clinical trials. 82 An example of a successful strategy for addressing the research needs in translational symptom research is presented in Figure 8 . It is based on the systematic studies of inflammation-induced depression that have been carried out during the past 10 years and illustrates how clinical findings can be used to guide preclinical mechanistic experiments of which the results provide new leads for intervention studies in the clinic. 83, 84 At the preclinical level, we have already seen that quite sophisticated animal models can be used to study the pathophysiology and treatment of cancer-related symptoms. On the clinical side, much still remains to be done to exploit the observation that not all patients who receive cancer therapy develop high levels of symptoms. The lower severity of symptoms in a significant proportion of cancer therapy-exposed patients challenges the notion that high symptom burden is a normative response to cancer therapy. It justifies the search for preexisting risk factors, and the consideration of whether characteristics that differentiate patients with high levels of symptoms from low levels of symptoms reflect these risk factors.
A pharmacogenomic or toxicogenomic approach has been proposed for identification of patients at high and low risk of development of chemotherapy-induced peripheral neurotoxicity. 85 Genes of interest are those that have an important role in detoxification of drugs (such as glutathione S transferase P1, glutathione S-transferase M1 and M3, and cytochrome P450 superfamily), in cancer cell resistance to platinum drugs (excision repair cross-complementing group 1), and in transport of drugs across extracellular and intracellular
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Lever press FR5 Figure 6 | Cancer-related fatigue and effort-related decision making. The two upper figures show the apparatus used to assess effort-related decisions based upon cost-benefit analyses. The rat is put in a chamber that allows access to a highly palatable food (condensed sweetened milk) providing it presses the left lever five times, while a less preferred food (lab chow) is freely available at the same time (top left and right). With a ratio requirement of five, control rats get most of their food from lever pressing (bottom left). By contrast, rats that have received chemotherapy and experience fatigue are expected to shift behaviour away from lever pressing and increase their consumption of lab food (bottom right membranes (ATP-binding cassette proteins). The results of this approach have so far been inconsistent. If inflammation is important in the development of behavioural co-morbidities in response to cancer therapy, the critical genes are not necessarily those that are involved in pharmacokinetics of the drugs and their penetration into the brain. Genes that influence intensity and duration of the inflammatory response and sensitivity of the central nervous system to inflammation should be more relevant. This relevance has been seen in the field of IFN-α-induced depression in patients with hepatitis C virus.
The probability of developing symptoms of depression was found to be a joint function of both cytokine and brain neurotransmitter risk factors. 86 There is preliminary evidence for a genetic association between IL-6 and TNF-α and the severity of sleep disturbances and morning fatigue in cancer patients. 87, 88 Other candidate genetic determinants for increased sensitivity of the brain to inflammatory injury involve the E4 allele of the apolipoprotein gene that compromises neuronal repair and plasticity, and polymorphism in the gene encoding the catechol-O-methyl transferase enzyme that regulates the amount of dopamine in the frontal Figure 7 | Motivational assessment in mice. Acute administration of IL-1β decreases the motivation to work for sweetened milk in mice in a progressive ratio test. In order to get access to a few drops of sweetened milk, mice have to insert their nose in the hole that is at the right of the feeder. When this is done 10 times in a row, mice get access to the milk and they can repeat this during a 30 min test (fixed ratio 10). In this test, IL-1β does not alter the response rate in doses varying from 10 to 300 ng (left diagram). In the progressive ratio 10 (right diagram), mice have to respond 10 times for the first reward, 20 times for the second reward, and so on with an increment of 10 after each reward. Saline-treated mice normally stop responding when they reach a ratio of 110 responses for a food reward. IL-1β administered at a dose of 100 or 300 ng decreases the maximum ratio mice are willing to work for. It is expected that chemotherapy will produce the same type of deficit. Figure 8 | Translational strategy of the pathophysiology of inflammation-associated depression. Clinical needs were identified on the basis of the high prevalence of symptoms of depression in patients with chronic inflammation. Measurement strategies were then identified to assess the phenomenology and time course of symptoms in a target population with a high prevalence of inflammation-induced depression. Cancer patients with metastatic kidney cancer or melanoma and treated chronically with IFN-α and/or IL-2 were selected for this purpose. Clinical biochemistry revealed that immune stimulation was associated with activation of a tryptophan-degrading pathway that was tentatively ascribed to activation of indoleamine 2,3 dioxygenase. Mechanistic studies in animal models of depression confirmed the causative role of inflammation in the development of depressive-like behaviour and the mediating role of indoleamine 2,3 dioxygenase activation. 83, 84 Similar associations between inflammation and activation of tryptophan-degrading pathway have now been confirmed in other disease conditions characterized by chronic inflammation. The possibility of targeting tryptophan-degrading pathways for treating inflammation-associated symptoms of depression is currently under investigation. cortex. 89 These genetic polymorphisms are associated with a higher risk of cognitive dysfunction in response to chemotherapy in breast cancer and lymphoma patients. 90 In view of the several thousands of genes that are involved in the production and function of cytokines and their differences of expression between individuals and tissues, it is difficult to imagine being able to grasp the complexity of the relationship between inflammation and symptoms by focusing on a few candidate genes. Functional genomic strategies are certainly worth considering in this context. They have already proven useful to replace the problematic study of 'stress response genes' , which were hypothesized to be reliably associated with psychological states such as acute stress, post-traumatic stress disorders, and depression, by focusing on higherorder themes that involve the biological causes and consequences of gene transcription. 91 This type of approach has revealed the existence of a biological residue manifested by decreased glucocorticoid and increased proinflammatory signalling in individuals with low early life socioeconomic status, which might explain the higher prevalence of chronic diseases associated with this condition. 92 Mining the inflammation genome will not be sufficient to explain cancer-related symptoms. Epigenetic modifications also need to be considered because environmentally-induced alterations in DNA methylation and histone acetylation can selectively activate or inactivate genes that control inflammation, such as the transcription factor (NF-KB). 93, 94 Conclusions Ultimately, the possibility of identifying genetic and epigenetic risk factors for developing symptoms in response to cancer therapy should allow personalization of cancer treatments as well as strategies for symptom control. Before this can be undertaken, it is necessary to make sure that the risk factors identified in patients have a causal role. This is where preclinical approaches have a vital role. Even if these two complementary approaches are feasible, it nonetheless remains that the present situation in which the causal factors and risk factors for develop ing symptoms in response to current cancer therapies are determined a posteriori is far from ideal. It would be much better to have an a priori know ledge of the exact mechanisms underlying neuro behavioural toxic effects of cancer therapy. This remains to be accomplished.
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